PDF(Sci-hub)
Abstract：
Tumor recurrence rate after surgery or ablation of hepatocellular carcinoma (HCC) is as high as 70%. However, there are no widely accepted adjuvant therapies; therefore, no treatment has been recommended by guidelines from the American Association for the Study of Liver Disease or the European Association for the Study of the Liver. All the registered trials failed to find any treatment to prolong recurrence-free survival, which is the primary outcome in most studies, including sorafenib. Some investigator-initiated studies revealed that anti-hepatitis B virus agents, interferon-α, transcatheter chemoembolization, chemokine-induced killer cells, and other treatments prolonged patient recurrence-free survival or overall survival after curative therapies. In this review, we summarize the current status of adjuvant treatments for HCC and explain the challenges associated with designing a clinical trial for adjuvant therapy. Promising new treatments being used as adjuvant therapy, especially anti-PD-1 antibodies, are also discussed.
摘要：
肝细胞癌(HCC)手术或消融后肿瘤复发率高达70%。然而,没有广泛接受的辅助疗法；因此，美国肝病研究协会或欧洲肝病研究协会的指南均未推荐治疗.所有注册的试验都没有找到任何延长无复发生存期的治疗方法，这是大多数研究的主要结果，包括索拉非尼.一些研究者发起的研究表明，抗乙型肝炎病毒药物，干扰素-α，经导管化疗栓塞,趋化因子诱导的杀伤细胞，和其他治疗延长了患者的无复发生存期或治愈性治疗后的总生存期.在这次审查中,我们总结了HCC辅助治疗的现状，并解释了与设计辅助治疗临床试验相关的挑战。有希望的新治疗方法被用作辅助治疗，尤其是抗PD-1抗体,也讨论了。
